Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-2990 in ANCA-Associated Vasculitis
NCT06196905Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Jun 2024
- Primary completion
- Jan 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT-2990 in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Mitsubishi Tanabe Pharma. Primary endpoints: Change from baseline in Birmingham Vasculitis Activity Score up to 24 weeks, Proportion of subjects who achieve Birmingham Vasculitis Activity Score of 0 up to 24 weeks and 17 more. Started Jun 2024; status: completed.
02
Drugs
MT-2990
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06196905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06196905.